Quick Answer
PMV Pharmaceuticals, Inc. reported Earnings Per Share Diluted of $1.48 (loss) per share for the year ending 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -29.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from PMV Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $0.33 (loss) per share | Q1 2022: $0.41 (loss) per share | Q2 2022: $0.38 (loss) per share | Q3 2022: $0.40 (loss) per share | Q1 2023: $0.42 (loss) per share | Q2 2023: $0.38 (loss) per share | Q3 2023: $0.34 (loss) per share | Q1 2024: $0.30 (loss) per share | Q2 2024: $0.02 (loss) per share | Q3 2024: $0.37 (loss) per share | Q1 2025: $0.34 (loss) per share | Q2 2025: $0.41 (loss) per share | Q3 2025: $0.40 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), PMV Pharmaceuticals, Inc.'s Earnings Per Share Diluted has grown by 38.3%.
- Historical annual values: Fiscal year 2025: $1.48 (loss) per share | Fiscal year 2024: $1.14 (loss) per share | Fiscal year 2023: $1.44 (loss) per share | Fiscal year 2022: $1.61 (loss) per share | Fiscal year 2021: $1.28 (loss) per share | Fiscal year 2020: $2.40 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: